Form 4: RenovoRx CEO Shaun Bagai Granted Stock Options

RenovoRx CEO Shaun Bagai was granted stock options to purchase 409,992 shares of the company's common stock, vesting over four years.

Summary

• On April 14, 2025, RenovoRx granted CEO Shaun Bagai stock options to purchase 409,992 shares of common stock.
• The options vest monthly over four years, starting January 1, 2025.
• 187,812 shares are incentive stock options, and 222,180 are non-qualified stock options.
• The exercise price is $0.8448 per share.
• The options become exercisable only when a registration statement covering the underlying shares is effective.
• The options will be fully vested by January 1, 2029, and expire on April 14, 2035.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, suggesting stability and alignment of interests. The sentiment is neutral to positive.

Positives

• The grant of stock options aligns the CEO's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the CEO.

Risks

• The options are not exercisable until a registration statement is effective, which introduces uncertainty.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting and expiration dates of the options.

Industry Context

Stock option grants are a common practice in the biotech industry to incentivize and retain key executives. The size and terms of the grant are typical for a CEO of a company of RenovoRx's size and stage.

Comparison to Industry Standards

• Stock option grants for CEOs in similar-sized biotech companies typically range from 1% to 5% of outstanding shares.
• Vesting schedules of four years with monthly vesting are standard practice.
• Comparable companies like Galera Therapeutics or Onconova Therapeutics also utilize stock options as part of their executive compensation packages.

Stakeholder Impact

• Shareholders may view the option grant as a positive incentive for the CEO.
• Employees may see the grant as a sign of confidence in the company's future.

Next Steps

• The options will vest over the next four years, subject to the terms of the grant.
• The options will become exercisable upon the effectiveness of a registration statement.

Key Dates

Keywords

stock options, RenovoRx, Shaun Bagai, CEO, equity compensation, RNXT, vesting